{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:10Z","timestamp":1787181910158,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119815","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:34:21Z","timestamp":1785936861000},"page":"119815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Aspirin hyporesponsiveness in type 2 diabetes mellitus: A systematic review with narrative synthesis of definitions, assessment methods, and clinical relevance"],"prefix":"10.1016","volume":"202","author":[{"given":"Laura","family":"Ortega-Hombrados","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mart\u00edn-Aurioles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"S\u00e1nchez-T\u00e9var","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"V\u00e1zquez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Monsalud","family":"Arrebola-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Rodr\u00edguez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Pedro","family":"De La Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Gonz\u00e1lez-Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119815_bib1","series-title":"International Diabetes Federation, IDF Diabetes Atlas","year":"2025"},{"key":"10.1016\/j.biopha.2026.119815_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40256-025-00761-w","article-title":"Definition, classification, diagnosis, and management of an emerging threat: cardio-renal-metabolic syndrome","volume":"26","author":"Koufakis","year":"2026","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.biopha.2026.119815_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00125-021-05590-5","article-title":"Kidney outcomes and all-cause mortality in people with type 2 diabetes exhibiting non-albuminuric kidney insufficiency","volume":"65","author":"Yamamoto","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2026.119815_bib4","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119815_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/dme.70218","article-title":"Prognostic models for all-cause and cardiovascular mortality in type 2 diabetes: systematic review","volume":"43","author":"Kundu","year":"2026","journal-title":"Diabet. Med."},{"key":"10.1016\/j.biopha.2026.119815_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/21501319241309168","article-title":"Metabolic syndrome: an updated review on diagnosis and treatment for primary care clinicians","volume":"15","author":"Peterseim","year":"2024","journal-title":"J. Prim. Care Community Health"},{"key":"10.1016\/j.biopha.2026.119815_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.33549\/physiolres.932672","article-title":"Monitoring of glycation, oxidative stress and inflammation in relation to the occurrence of vascular complications in patients with type 2 diabetes mellitus","volume":"63","author":"Jaku\u0161","year":"2014","journal-title":"Physiol. Res."},{"key":"10.1016\/j.biopha.2026.119815_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MED.0000000000000933","article-title":"Biomarkers and therapies to target endothelial dysfunction in type 2 diabetes: moving a step forward","volume":"33","author":"Chee","year":"2026","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.biopha.2026.119815_bib9","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s13300-025-01801-z","article-title":"Diabetic platelets: pathophysiology, clinical significance, and therapeutic perspectives","volume":"16","author":"Sharma","year":"2025","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.biopha.2026.119815_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/11795514231220780","article-title":"Cardiometabolic risk factors associated with type 2 diabetes mellitus: a mechanistic insight","volume":"16","author":"Chakraborty","year":"2023","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"10.1016\/j.biopha.2026.119815_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1724965","article-title":"Mechanism-guided pharmacotherapy for cardiometabolic multimorbidity: from pathophysiology to phenotype-prioritized treatment","volume":"16","author":"Dong","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2026.119815_bib12","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119815_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/eurheartj\/ehaf718","article-title":"Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?","volume":"47","author":"Galli","year":"2026","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2026.119815_bib14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/eurjpc\/zwae038","article-title":"Impact of the 2021 European Society of Cardiology prevention guideline's stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease","volume":"31","author":"Holtrop","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.biopha.2026.119815_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100675","article-title":"Needs-based considerations for the role of low-dose aspirin along the cardiovascular risk continuum","volume":"18","author":"Santilli","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.biopha.2026.119815_bib16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/bph.14196","article-title":"Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond)","volume":"176","author":"Crescente","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119815_bib17","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers","volume":"37","author":"Cox","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.biopha.2026.119815_bib18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jacc.2005.06.058","article-title":"Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease","volume":"46","author":"Maree","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2026.119815_bib19","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1111\/j.1538-7836.2010.03997.x","article-title":"The role of weight and enteric coating on aspirin response in cardiovascular patients","volume":"8","author":"Peace","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2026.119815_bib20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/cpt.874","article-title":"Lack of bioequivalence among low-dose, enteric-coated aspirin preparations","volume":"103","author":"Cox","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119815_bib21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/09537104.2019.1667495","article-title":"Weight as an assay-independent predictor of poor response to enteric aspirin in cardiovascular patients","volume":"31","author":"McCall","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.biopha.2026.119815_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1467-789X.2011.00930.x","article-title":"Platelet activation in obesity and the metabolic syndrome","volume":"13","author":"Santilli","year":"2012","journal-title":"Obes. Rev."},{"key":"10.1016\/j.biopha.2026.119815_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.medcli.2013.09.034","article-title":"Antiplatelet therapy: resistance to traditional antiaggregation drugs and role of new antiplatelet agents","volume":"143","author":"del Castillo-Carnevali","year":"2014","journal-title":"Med. Clin. (Barc. )"},{"key":"10.1016\/j.biopha.2026.119815_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078093","article-title":"The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis","volume":"8","author":"Weng","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119815_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2040622311400116","article-title":"Recommending aspirin for primary prevention in diabetic patients: what may we conclude from the data?","volume":"2","author":"Nicolucci","year":"2011","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.biopha.2026.119815_bib26","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.2337\/db07-0707","article-title":"The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study","volume":"56","author":"DiChiara","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2026.119815_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dme.12828","article-title":"Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with type 2 diabetes","volume":"33","author":"Bethel","year":"2016","journal-title":"Diabet. Med."},{"key":"10.1016\/j.biopha.2026.119815_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","article-title":"Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus","volume":"69","author":"Bhatt","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2026.119815_bib29","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2026.119815_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/ijcp.12310","article-title":"Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function","volume":"68","author":"Raghavan","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.biopha.2026.119815_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.phrs.2013.04.010","article-title":"Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study","volume":"74","author":"Karolczak","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2026.119815_bib32","first-page":"617","article-title":"Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus","volume":"16","author":"Ariturk","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2026.119815_bib33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1365-2710.2009.01083.x","article-title":"L.A. ElSafady, Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors","volume":"37","author":"Salama","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2026.119815_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1747-4949.2012.00929.x","article-title":"Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events","volume":"8","author":"Yi","year":"2013","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.biopha.2026.119815_bib35","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1111\/j.1538-7836.2007.02728.x","article-title":"Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin","volume":"5","author":"Evangelista","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2026.119815_bib36","first-page":"4599","article-title":"Diabetes and platelet response to low-dose aspirin","volume":"103","author":"Al-Sofiani","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2026.119815_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006050","article-title":"Reduced antiplatelet effect of aspirin does not predict cardiovascular events in patients with stable coronary artery disease","volume":"6","author":"Larsen","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2026.119815_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.5414\/CP202637","article-title":"Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical study","volume":"55","author":"Eskandarian","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119815_bib39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12975-017-0568-9","article-title":"Proteinuria predicts resistance to antiplatelet therapy in ischemic stroke","volume":"9","author":"George","year":"2018","journal-title":"Transl. Stroke Res."},{"key":"10.1016\/j.biopha.2026.119815_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1562","article-title":"Association of aspirin resistance with 4-hydroxynonenal and its impact on recurrent cerebral infarction in patients with acute cerebral infarction","volume":"10","author":"Guo","year":"2020","journal-title":"Brain Behav."},{"key":"10.1016\/j.biopha.2026.119815_bib41","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1097\/MJT.0000000000000869","article-title":"Correlation of cardiovascular risk factors and biomarkers with platelet reactivity in coronary artery disease","volume":"26","author":"Bobescu","year":"2019","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.biopha.2026.119815_bib42","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.diabet.2019.11.002","article-title":"Determinants of aspirin resistance in patients with type 2 diabetes","volume":"46","author":"Paven","year":"2020","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.biopha.2026.119815_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40618-013-0012-2","article-title":"Resistance to acetylsalicylic acid in patients with type 2 diabetes mellitus is associated with lipid disorders and history of current smoking","volume":"37","author":"Labuz-Roszak","year":"2014","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.biopha.2026.119815_bib44","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2014.01.015","article-title":"Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes","volume":"234","author":"Kim","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2026.119815_bib45","doi-asserted-by":"crossref","first-page":"494","DOI":"10.5603\/CJ.2012.0090","article-title":"Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes?","volume":"19","author":"Postula","year":"2012","journal-title":"Cardiol. J."},{"key":"10.1016\/j.biopha.2026.119815_bib46","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/eurheartj\/ehaf680","article-title":"Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial","volume":"47","author":"Dillinger","year":"2026","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2026.119815_bib47","doi-asserted-by":"crossref","first-page":"11317","DOI":"10.3390\/ijms231911317","article-title":"Aspirin resistance in vascular disease: a review highlighting the critical need for improved point-of-care testing and personalized therapy","volume":"23","author":"Khan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119815_bib48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12933-018-0783-z","article-title":"Platelet activity and hypercoagulation in type 2 diabetes","volume":"17","author":"Pretorius","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2026.119815_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-018-0763-3","article-title":"Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies","volume":"17","author":"Kaur","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2026.119815_bib50","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.bbrc.2014.05.029","article-title":"P66Shc mediates increased platelet activation and aggregation in hypercholesterolemia","volume":"449","author":"Kumar","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119815_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1221438","article-title":"Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies","volume":"10","author":"Das","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.biopha.2026.119815_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00001721-200206000-00001","article-title":"Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100","volume":"13","author":"Roller","year":"2002","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.biopha.2026.119815_bib53","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","article-title":"Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin","volume":"127","author":"Grosser","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119815_bib54","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119815_bib55","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119815_bib56","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jcpt.12838","article-title":"Aspirin resistance mediated by oxidative stress-induced 8-isoprostaglandin F2","volume":"44","author":"Guo","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2026.119815_bib57","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ab.2009.10.014","article-title":"Simultaneous quantification of 8-iso-prostaglandin-F2\u03b1 and 11-dehydro thromboxane B2 in human urine by liquid chromatography\u2013tandem mass spectrometry","volume":"397","author":"Cavalca","year":"2010","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.biopha.2026.119815_bib58","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jdiacomp.2016.01.003","article-title":"The effects of garlic extract upon endothelial function, vascular inflammation, oxidative stress and insulin resistance in adults with type 2 diabetes at high cardiovascular risk: a pilot double blind randomized placebo controlled trial","volume":"30","author":"Atkin","year":"2016","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.biopha.2026.119815_bib59","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.biopha.2016.06.044","article-title":"The effectiveness of antioxidant therapy in aspirin resistance, diabetes population for prevention of thrombosis","volume":"83","author":"Aboonabi","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119815_bib60","article-title":"Clinical predictors of aspirin resistance in patients with type 2 diabetes: systematic review and meta-analysis","volume":"26","author":"Zhang","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2026.119815_bib61","doi-asserted-by":"crossref","DOI":"10.3310\/hta19370","article-title":"The prognostic utility of tests of platelet function for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation","volume":"19","author":"Dretzke","year":"2015","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.biopha.2026.119815_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.62347\/IBGQ2413","article-title":"Association of ABCB1 gene polymorphisms with aspirin or clopidogrel resistance in ischemic stroke: a meta-analysis","volume":"18","author":"Lv","year":"2025","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.biopha.2026.119815_bib63","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.2337\/dc26-S010","article-title":"American Diabetes Association Professional Practice Committee, Cardiovascular disease and risk management: standards of care in diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2026.119815_bib64","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur. Heart J."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:53:28Z","timestamp":1787180008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":64,"alternative-id":["S0753332226008516"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119815","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin hyporesponsiveness in type 2 diabetes mellitus: A systematic review with narrative synthesis of definitions, assessment methods, and clinical relevance","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119815"}}